Related Experiment Video
Updated: Apr 28, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
8.0K
Genetic polymorphisms associated with antiepileptic metabolism
Miguel A Lopez-Garcia1, Iris A Feria-Romero1, Hector Fernando-Serrano1
1Doctoral Biological and Health Sciences, Metropolitan Autonomous University, Mexico City, Mexico.
Frontiers in Bioscience (Elite Edition)
|June 5, 2014
Summary
Genetic variations in cytochrome P450 enzymes impact how individuals respond to antiepileptic drugs (AEDs). Understanding these pharmacogenetic factors is crucial for optimizing AED therapy and reducing toxicity risks.
Area of Science:
- Pharmacogenetics
- Molecular Biology
- Clinical Pharmacology
Background:
- Inter-individual variability in drug response is influenced by pharmacogenetics.
- Cytochrome P450 (CYP) enzymes are key in metabolizing many antiepileptic drugs (AEDs).
- Genetic variants (polymorphisms) in CYP enzymes can alter drug concentrations and clinical outcomes.
Purpose of the Study:
- To review evidence on how CYP genetic polymorphisms affect AED clinical action.
- To highlight the role of CYP2C9 and CYP2C19 in AED metabolism.
- To guide future research in epilepsy pharmacogenetics.
Main Methods:
- Conducted keyword searches in PubMed, Medscape, Rxlisty, and PharmGKB for genetic polymorphisms.
- Utilized the NCBI website for CYP450 allele nomenclature.
- Reviewed existing literature on CYP involvement in AED metabolism.
Main Results:
- CYP2D6, CYP2C9, CYP3A4, and CYP2C19 are significantly involved in metabolizing most AEDs.
- Allele frequencies and associated clinical response variability were considered.
- Polymorphisms in these CYPs are linked to variations in AED efficacy and toxicity.
Conclusions:
- Pharmacogenetic variations, particularly in CYP enzymes, play a vital role in AED response.
- Further investigation into CYP polymorphisms is essential for personalized epilepsy treatment.
- Understanding these genetic factors can help mitigate AED-related adverse events.
More Related Videos
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
337
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
337
01:27Principles of Pharmacogenetics: Types of Genetic Variants
137
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189